D
Do Young Kim
Researcher at Yonsei University
Publications - 737
Citations - 18320
Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.
Papers
More filters
Patent
Flexible display including protective coating layer having different thickness in bend section
Heungju Jo,JeongKweon Park,Park Chan,Lee Sanggul,Yong Soo Kim,Jangcheol Kim,Do Young Kim,Euijun Lee,Han Sangeun +8 more
TL;DR: A flexible display device can include a first portion in which an organic light emitting element is disposed on a first surface; a base layer made of a flexible substrate including a second portion, outside of the first portion, having a bend section bent toward a second surface opposite to the first surface as mentioned in this paper.
Journal ArticleDOI
Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial.
Eun Ju Cho,Su Jong Yu,So Young Kwon,Ji Hoon Kim,Do Young Kim,Won Kim,June Sung Lee,Jin-Woo Lee,Youn Jae Lee,Hee Bok Chae,Jung Hwan Yoon +10 more
TL;DR: In patients with virological response under entecavir therapy, concomitant food intake did not affect the antiviral efficacy and for patients with adherence problem, taking entecvir with food may be considered to improve compliance.
Journal ArticleDOI
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study.
Chang Hun Lee,Gwang Hyeon Choi,Hwa Young Choi,Sojung Han,Eun Sun Jang,Young Eun Chon,Young Chang,Kyung-Ah Kim,Do Young Kim,Hyung J. Kim,Hye Lin Kim,Sook Hyang Jeong,In Hee Kim +12 more
TL;DR: In this article , the authors investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea and analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Journal ArticleDOI
Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone
Jun Yong Park,Choon Ok Kim,Eun Sil Oh,Jung Il Lee,Ja Kyung Kim,Sang Hoon Ahn,Do Young Kim,Seung U. Kim,Beom Kyung Kim,Y E Chung,Se mi Kim,Min Soo Park +11 more
TL;DR: Lobeglitazone may be safely used in patients with mild or moderate HI without dose adjustment without adverse events or tolerability issues, and should be used cautiously in these patients with hepatic impairment and healthy matched controls.
Journal ArticleDOI
Transarterial Radioembolization versus Tyrosine Kinase Inhibitor in Hepatocellular Carcinoma with Portal Vein Thrombosis.
Moon-Haeng Hur,Yuri Cho,Do Young Kim,Jae Seung Lee,Gyoung Min Kim,Hyo Cheol Kim,Dong Hyun Sinn,Dongho Hyun,Yeon Seok Seo,In Joon Lee,Joong-Won Park,Yoon Jun Kim +11 more
TL;DR: In this paper , the authors compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced hepatocellular carcinoma (HCC) and segmental or lobar PVTT.